

## Onkologie

- 2 **Karcinom prsu s HER2 pozitivitou s hormonálními receptory pozitivními i negativními – novinky v neoadjuvantní léčbě**  
prof. MUDr. Jitka Abrahámová, DrSc. Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
- 2 **Neoadjuvantní systémová léčba u pacientek s karcinomem prsu**  
MUDr. Katarína Petráková, Ph.D. Klinika komplexní onkologické péče, MOÚ Brno
- 3 **Bevacizumab – nová možnost léčby pokročilého karcinomu děložního čípku**  
doc. MUDr. Jana Prausová, Ph.D., MBA Onkologická klinika 2. LF UK a FN v Motole, Praha
- 3 **Biologická léčba melanomu**  
MUDr. Eugen Kubala Klinika onkologie a radioterapie FN Hradec Králové
- 3 **Význam hormonálních léčiv v sekvenční léčbě metastazujícího CRPC**  
MUDr. Jiří Slíva Ústav farmakologie 3. LF UK, Praha
- 4 **Karcinom prostaty a možnosti ovlivnění přežití – systémová a sekvenční léčba**  
MUDr. Ivo Kocák, Ph.D. | doc. MUDr. Ilona Kocáková, Ph.D. | MUDr. Stanislav Špalda  
Klinika komplexní onkologické péče MOÚ a LF MU, Brno
- 4 **Cílená léčba metastatického kolorektálního karcinomu v roce 2015**  
MUDr. Jiří Tomášek Klinika komplexní onkologické péče MOÚ, Brno
- 4 **Léčebné možnosti metastatického kolorektálního karcinomu**  
MUDr. Jiří Bartoš, MBA | MUDr. Igor Richter, Ph.D. Komplexní onkologické centrum Krajské nemocnice Liberec, a. s.
- 5 **Systémová terapie nádorů hlavy a krku**  
MUDr. Zdeněk Mechl, CSc. | MUDr. Dagmar Brančíková Interní hematologická a onkologická klinika LF MU a FN Brno-Bohunice
- 6 **Výživa onkologických pacientů**  
MUDr. Petra Holečková, Ph.D., MBA Ústav radiační onkologie Nemocnice Na Bulovce a 1. LF UK, Praha
- 6 **Průlomová bolest z pohledu radiačního onkologa**  
MUDr. Magda Macháňová Komplexní onkologické centrum, Krajská nemocnice Liberec, a. s.
- 6 **Dolforin v léčbě silné chronické bolesti u onkologických pacientů**  
prof. MUDr. Jindřich Fínek, Ph.D. Onkologická a radioterapeutická klinika FN a LF UK, Plzeň
- 6 **Léčba bendamustinem: znovuzrození starého léku**  
MUDr. Kateřina Steinerová | doc. MUDr. Daniel Lysák, Ph.D. | MUDr. Pavel Jindra, Ph.D.  
Hematologicko-onkologické oddělení, FN Plzeň

# Karcinom prsu s HER2 pozitivitou s hormonálními receptory pozitivními i negativními – novinky v neoadjuvantní léčbě

prof. MUDr. Jitka Abrahámová, DrSc. Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

- 1 *Zhoubné novotvary 2011*, ÚZIS, Praha 2015.
- 2 **Abrahámová, J.**: Adjuvantní hormonální léčba časného karcinomu prsu u postmenopauzálních žen. *Farmakoterapie*, 2005, dopl. 1, s. 69–79.
- 3 **Abrahámová, J.**: Pokročilý karcinom prsu. *ACTA MEDICINAE*, 2015, 3, s. 44–50.
- 4 **von Minckwitz, G. – Untch, M. – Blohmer, J. U., et al.**: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J Clin Oncol*, 2012, 30, s. 1796–1804.
- 5 **Esserman, L. J. – Berry, D. A. – DeMichele, A., et al.**: Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: result from the I-SPY 1 TRIAL-CALGB 150007/150012. *ACRIN 6657. J Clin Oncol*, 2012, 30, s. 3242–3249.
- 6 **Cortazar, P. – Zhang, L. – Untch, M., et al.**: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet Epub*, 14. 2. 2014.
- 7 **Gianni, L. – Eiermann, W. – Semiglazov, V., et al.**: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. *Lancet*, 2010, 375, s. 377–384.
- 8 **Gianni, L. – Eiermann, W. – Semiglazov, V., et al.**: Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Dostupné z: [www.thelancet.com/onlinepub/doi.fullarticle.aspx?doi=10.1016/S1473-2045\(14\)70080-4](http://www.thelancet.com/onlinepub/doi.fullarticle.aspx?doi=10.1016/S1473-2045(14)70080-4).
- 9 **Baselga, J. – Bradbury, I. – Eidtmann, H., et al.**: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open label, multicentre, phase 3 trial. *Lancet*, 2012, 379, s. 633–640.
- 10 **Piccart-Gebhart, M. J. – Holme, A. P. – Baselga, J., et al.**: First result from the phase III ALTO trial (BIG 2-06; NCCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). *J Clin Oncol*, 2014, 32, s. 5s (dopl.); abstrakt LBA4.
- 11 **de Azambuja, E. – Holme, A. P. – Piccart-Gebhart, M., et al.**: Lapatinib with trastuzumab for HER2 positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. *Lancet Oncol*, 2014, 15, s. 1137–1146.
- 12 **Berry, D. A.**: In NeoALTTO & ALTO Trials, Neoadjuvant Response Predicts Adjuvant. *The Cancer Letter*. Dostupné z: [www.cancerletter.com/articles/20140711\\_2](http://www.cancerletter.com/articles/20140711_2), vyhledáno 11. 7. 2014.
- 13 **Sweeting, R. S. – Klauber-Demore, N. – Meyers, M. O., et al.**: Young women with locally advanced breast cancer who achieve breast conservation after neoadjuvant chemotherapy have a low local recurrence rate. *Am Surg*, 2011, 77, s. 850–855.
- 14 **Gianni, L. – Pienkowski, T. – Im, Y. H., et al.**: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. *Lancet Oncol*, 2012, 13, s. 25–32.
- 15 **Schneeweiss, A. – Chia, S. – Hickish, T., et al.**: Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomised phase II cardiac safety study (TRYPHAENA). *Ann Oncol*, 2013, 24, s. 2278–2284.
- 16 U.S. Food and Drug Administration. *FDA approves Perjeta for neoadjuvant breast cancer treatment*. Dostupné z: [www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm370393.htm](http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm370393.htm), vyhledáno 3. 3. 2015.
- 17 **Gradishar, W. J. – Anderson, B. O., et al.**: *NCCN clinical practice guidelines in oncology: Breast Cancer Version 3.2014*. Dostupné z: <http://nccn.org>, vyhledáno 7. 2. 2015.
- 18 **Swain, S. M. – Baselga, J. – Kim, S. B., et al.**: Pertuzumab, trastuzumab and docetaxel in HER2-positive metastatic breast cancer. *N Engl J Med*, 2015, 372, s. 724–734.

## Neoadjuvantní systémová léčba u pacientek s karcinomem prsu

MUDr. Katarína Petráková, Ph.D. Klinika komplexní onkologické péče, MOÚ Brno

- 1 **Diates, A. S. – Winer, E. – Goldhirsch, A., et al.**: Tailoring therapy-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. *Ann Oncol*, 2015, 26, s. 1533–1546.
- 2 **Von Minckwitz, G. – Untch, M. – Blohmer, J. U., et al.**: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J Clin Oncol*, 2012, 30, s. 1796–1804.
- 3 Dostupné z: [www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm305501.pdf](http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm305501.pdf), vyhledáno 3. 9. 2015.
- 4 **Berruti, A. – Amoroso, V. – Gallo, F., et al.**: Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. *J Clin Oncol*, 2014, 32, s. 3883–3891.
- 5 **Cortazar, P. – Zhang, L. – Untch, M., et al.**: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet*, 2014, 384, s. 164–172.
- 6 **Piccart-Gebhart, M. – Holme, P. A. – Baselga, J., et al.**: First results from the phase III ALTO trial (BIG 2e06; NCCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T+L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). *J Clin Oncol*, 2014, 32, dopl., abstrakt LBA4.
- 7 **Goldhirsch, A. – Wood, W. C. – Diates, A. S., et al.**: Panel Members. Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. *Ann Oncol*, 2011, 22, s. 1736–1747.
- 8 **Polley, M. Y. – Lejny, S. C. – Gao, D., et al.**: An international study to increase concordance in Ki67 scoring. *Mod Pathol*, 28, s. 778–786.
- 9 **Denkert, C. – Budczies, J. – von Minckwitz, G., et al.**: Strategies for developing Ki67 as useful biomarker in breast cancer. *The Breast*, 2015, dx.doi.org/10.1016/j.breast.2015.07.017.
- 10 **Hind, D. – Tyld, L. – Beverley, C. B., et al.**: Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). *Cochrane Database Syst Rev*, 2006, CD004272.
- 11 **Dowsett, M. – Smith, I. E. – BBS, S. R., et al.**: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. *J Natl Cancer Inst*, 2007, 99, s. 167–170.
- 12 **Eiermann, W. – Paepke, S. – Appfelstaedt, J., et al.**: Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. *Ann Oncol*, 2001, 12, s. 1527–1532.
- 13 **Semiglazov, V. – Kletsel, A. – Semiglazov, V.**: Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0). *J Clin Oncol*, 2005, 23, 165 (abstrakt 530).
- 14 **Ellis, M. E. – Suman, V. J. – Hoog, J., et al.**: Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. *J Clin Oncol*, 2011, 29, s. 2342–2349.
- 15 **Sapranò, J. – Zhao, F. – Martino, S., et al.**: Evaluating of the role of taxane and schedule in operable breast cancer. *J Clin Oncol*, 33, s. 2353–2360.
- 16 **von Minckwitz, G. – Schneeweiss, A. – Loibl, S., et al.**: Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. *Lancet Oncol*, 2014, 15, s. 747–756.
- 17 **Sikov, W. M. – Berry, D. A. – Perou, C. M., et al.**: Impact of the addition of carboplatin and/or bevazuzumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple negative breast cancer: CALGB 40603 (Alliance). *J Clin Oncol Off J Am Soc Clin Oncol*, 2015, 33, s. 13–21.
- 18 **Denkert, C. – von Minckwitz, G. – Brase, J. C., et al.**: Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. *J Clin Oncol*, 2015, 33, s. 983–991.
- 19 **Gianni, L. – Eiermann, W. – Semiglazov, V., et al.**: Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2 positive locally advanced breast cancer. Prezentováno na ASCO Annual Meeting 2013. *J Clin Oncol*, 2013, dopl., abstrakt 503.
- 20 **Untch, M. – Rezaei, M. – Loibl, S., et al.**: Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. *J Clin Oncol*, 2010, 28, s. 2024–2031.
- 21 **Schneeweiss, A. – Chia, S. – Hickish, T., et al.**: Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). *Ann Oncol*, 2013, 24, s. 2278–2284.
- 22 **Luca, G. – Pienkowski, T. – Young-Hyuck, I., et al.**: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. *Lancet Oncology*, 2012, 13, s. 25–32, DOI: 10.1016/S1473-2045(11)70336-9.

# Bevacizumab – nová možnost léčby pokročilého karcinomu děložního čípku

doc. MUDr. Jana Prausová, Ph.D., MBA Onkologická klinika 2. LF UK a FN v Motole, Praha

- 1 www.svod.cz
- 2 Schlichte, M. F., et al.: Current cervical carcinoma screening guidelines. *J Clin Med*, 2015, 4, s. 918–932.
- 3 Fusco, E., et al.: History of colposcopy: a brief biography of Hinselmann. *J Prenat Med*, 2008, 2, s. 19–23.
- 4 Papanikolaou, G. N. – Traut, H. F.: Diagnosis of uterine cancer by the vaginal smear. *Yale J Biol Med*, 1943, 15, s. 924.
- 5 zur Hausen, H.: Papillomaviruses and cancer: from basic studies to clinical application. *Nature Reviews Cancer*, 2002, 2, s. 342–350.
- 6 Tewari, M. D., et al.: Improved survival with bevacizumab in advanced cervical cancer. *N Engl J Med*, 2014, 370, s. 734–743.
- 7 SPC Avastin, www.sukl.cz.

## Biologická léčba melanomu

MUDr. Eugen Kubala Klinika onkologie a radioterapie FN Hradec Králové

- 1 Haluska, F. G. – Teak, H. – Wu, H., et al.: Genetic alteration in signaling pathways in melanoma. *Clin Cancer Res*, 2006, 12, s. 2301–2307.
- 2 Menzies, A. M. – Haydu, L. E. – Visintin, L., et al.: Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. *Clin Cancer Res*, 2012, 18, s. 3242–3249.
- 3 Long, G. V. – Menzies, A. M. – Nagrial, A. M., et al.: Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. *J Clin Oncol*, 2011, 29, s. 1239–1246.
- 4 Chapman, P. B. – Hauschild, A. – Robert, C., et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med*, 2011, 364, s. 2507–2516.
- 5 Hauschild, A. – Grob, J. J. – Demidov, L. V., et al.: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. *Lancet*, 2012, 380, s. 358–365.
- 6 Flaherty, K. T. – Puzanov, I. – Kim, K. B., et al.: Inhibition of mutated, activated BRAF in metastatic melanoma. *N Engl J Med*, 2010, 363, s. 809–819.
- 7 Patel, J. D. – Krilov, L. – Adams, S., et al.: Clinical cancer advances 2013: annual report on progress against cancer from the American Society of Clinical Oncology. *J Clin Oncol*, 2014, 32, s. 129–160.
- 8 Hauschild, A. – Grob, J. J. – Demidov, L. V., et al.: An update on BRAF-inhibitors in melanoma: a phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). *J Clin Oncol*, 2013, 31 (dopl., abstrakt 9013).
- 9 Chapman, P. B. – Hauschild, A. – Robert, C., et al.: Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine in previously untreated patients with BRAFV600E-mutated melanoma. *J Clin Oncol*, 2012, 30 (dopl., abstrakt 8502).
- 10 Ascierto, P. A. – Schadendorf, D. – Berlino, C., et al.: MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: anon-randomised, open-label phase 2 study. *Lancet Oncol*, 2013, 14, s. 249–256.
- 11 Flaherty, K. T. – Infante, J. R. – Daud, A., et al.: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. *N Engl J Med*, 2012, 367, s. 1694–1703.
- 12 Larkin, J. – Ascierto, P. A. – Dréno, B., et al.: Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. *N Engl J Med*, 2014, 371, s. 1867–1876.
- 13 Hoek, K. S. – Eichhoff, O. M. – Schlegel, N. C., et al.: In vivo switching of human melanoma cells between proliferative and invasive states. *Cancer Res*, 2008, 68, s. 650–656.
- 14 Emery, C. M. – Vijayendran, K. G. – Zipser, M. C., et al.: MEK1 mutations confer resistance to MEK and B-RAF inhibition. *Proc Natl Acad Sci U S A*, 2009, 106, s. 20411–20416.
- 15 Frederick, D. T. – Salas Fragomeni, R. A. – Schalck, A., et al.: Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. *PLoS One*, 2014, 9, s. e101286.
- 16 Haq, R. – Yokoyama, S. – Hawryluk, E. B., et al.: BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. *Proc Natl Acad Sci U S A*, 2013, 110, s. 4321–4326.
- 17 McArthur, G. A. – Zouny, R. J. – Sheppard, K. E., et al.: Clinical significance of genomic alterations of the CDK4-pathway and sensitivity to the CDK4 inhibitor PD 0332991 in melanoma. *J Clin Oncol*, 2012, 30 (dopl., abstrakt 8520).
- 18 Smalley, K. S. – Lioni, M. – Dalla Palma, M., et al.: Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. *Mol Cancer Ther*, 2008, 7, s. 2876–2883.
- 19 Chen, D. S. – Meloman, I.: Oncology meets immunology: the cancer-immunity cycle. *Immunity*, 2013, 39, s. 1–10.
- 20 Irving, B. A. – Cheung, J. – Yang, Y., et al.: MAP kinase inhibitors stimulate T cell and anti-tumor activity in combination with blockade of the PD-L1/PD-1 interaction. *J Immunother Cancer*, 2013, 1, abstrakt P79.

## Význam hormonálních léčiv v sekvenční léčbě metastazujícího CRPC

MUDr. Jiří Slíva Ústav farmakologie 3. LF UK, Praha

- 1 Schrader, A. J. – Boegemann, M. – Ohlmann, C. H., et al.: Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. *Eur Urol*, 2014, 65, s. 30–36.
- 2 Loriot, Y. – Bianchini, D. – Ileana, E., et al.: Antitumor activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). *Ann Oncol*, 2013, 24, s. 1807–1812.
- 3 Noonan, K. L. – North, S. – Bitting, R. L., et al.: Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. *Ann Oncol*, 2013, 24, s. 1802–1807.
- 4 Mostaghel, E. A. – Marck, B. T. – Plymate, S. R., et al.: Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. *Clin Cancer Res*, 2011, 17, s. 5913–5925.
- 5 Hu, R. – Lu, C. – Mostaghel, E. A., et al.: Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. *Cancer Res*, 2012, 72, s. 3457–3462.
- 6 Efsthathiou, E. – Titus, M. A. – Tsavachidou, D., et al.: MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: a preliminary report [abstract]. *J Clin Oncol*, 2011, 29, dopl. 15, s. 289.
- 7 Cai, C. – Chen, S. – Ng, P., et al.: Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. *Cancer Res*, 2011, 71, s. 6503–6513.
- 8 Efsthathiou, E. – Titus, M. – Tsavachidou, D., et al.: Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. *J Clin Oncol*, 2012, 30, s. 637–643.
- 9 Grasso, C. S. – Wu, Y. M. – Robinson, D. R., et al.: The mutational landscape of lethal castration-resistant prostate cancer. *Nature*, 2012, 487, s. 239–243.
- 10 Maines, F. – Cardo, O. – Vecchia, A. – Bria, E.: Sequential use of new agents (NAs) after docetaxel (DOC) first line in metastatic castration-resistant prostate cancer. *Journal of Clinical Oncology*, 2015, Genitourinary Cancers Symposium, 26–28. 2. 2015, 33, dopl., s. 258.
- 11 Oudard, S. – Angelelguies, A. – Maeso, I. G., et al.: Prognostic factors for survival and sequencing of life extending therapies in mCRPC patients in post-docetaxel setting. *ESMO*, 2014, abstrakt 789 P.

# Karcinom prostaty a možnosti ovlivnění přežití – systémová a sekvenční léčba

MUDr. Ivo Kocák, Ph.D. | doc. MUDr. Ilona Kocáková, Ph.D. | MUDr. Stanislav Špalda  
Klinika komplexní onkologické péče MOÚ a LF MU, Brno

- 1 Tannock, I. F. – Osoba, D. – Stockler, M. R., et al.: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. *J Clin Oncol*, 1996, 14, s. 1756–1764.
- 2 Tannock, I. F. – de Wit, R. – Berry, W. R., et al.: TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Engl J Med*, 2004, 351, s. 1502–1512.
- 3 Sweeney, Ch. – Yu-Hui, Ch. – Carducci, M. A., et al.: Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa). An ECOG-led phase III randomized trial. 2014 ASCO Annual Meeting. *J Clin Oncol*, 2014, 32, dopl., abstrakt LBA2.
- 4 de Bono, J. S. – Oudard, S. – Ozguroglu, M., et al.: TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. *Lancet*, 2010, 2, 376, s. 1147–1154.
- 5 Fizazi, K. – Scher, H. I. – Molina, A., et al.: COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. *Lancet Oncol*, 2012, 13, s. 983–992.
- 6 Ryan, C. J. – Smith, M. R. – de Bono, J. S., et al.: COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. *N Engl J Med*, 2013, 368, s. 138–148.
- 7 Scher, H. I. – Fizazi, K. – Saad, F., et al.: AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med*, 2012, 367, s. 1187–1197.
- 8 Loriot, Y. – Miller, K. – Sternberg, C. N., et al.: Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (PREVALE): results from a randomised, phase 3 trial. *Lancet Oncol*, 14, 4, 2015, pii: S1470-2045(15)70113-0, doi: 10.1016/S1470-2045(15)70113-0 (Epub před tiskem).
- 9 Maines, F. – Cardo, O. – Vecchia, A. – Bria, E.: Sequential use of new agents (NAs) after docetaxel (DOC) first line in metastatic castration-resistant prostate cancer. *Journal of Clinical Oncology*, 2015, Genitourinary Cancers Symposium, 26–28. 2. 2015, 33, dopl., s. 258.
- 10 Oudard, S. – Angelergues, A. – Maeso, I. G., et al.: Prognostic factors for survival and sequencing of life extending therapies in mCRPC patients in post-docetaxel setting. ESMO, 2014, abstrakt 789 P.

## Cílená léčba metastatického kolorektálního karcinomu v roce 2015

MUDr. Jiří Tomášek Klinika komplexní onkologické péče MOÚ, Brno

- 1 ÚZIS ČR.
- 2 Van Cutsem, E. – Tabernero, J. – Lakomy, R., et al.: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. *J Clin Oncol*, 2012, 30, s. 3499–3506.
- 3 Tabernero, J. – Toshiro, T. – John, A. L., et al.: Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. *Lancet Oncol*, 2015, 16, s. 499–508.
- 4 Grothey, A. – Van Cutsem, E. – Sobrero, A., et al.: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet*, 2013, 381, s. 303–312.
- 5 Heinemann, V. – von Weikersthal, L. F. – Decker, T., et al.: Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). *Proc Am Soc Clin Oncol*, 2013, 31, LBA3506.
- 6 Stintzing, S. – Jung, A. – Rossius, L., et al.: Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. 2013 European Cancer Congress, abstrakt 17, prezentováno 28. 9. 2013.
- 7 Heinemann, V. – von Weikersthal, L. F. – Decker, T., et al.: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. *Lancet Oncol*, 2014, 15, s. 1065–1075.
- 8 Schwartzberg, L. S. – Rivera, F. – Karthaus, M., et al.: PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. *J Clin Oncol*, 2014, 32, s. 2240–2247.
- 9 Venook, A. P. – Niedzwiecki, D. – Lenz, H. J., et al.: CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (mCRC). *Proc Am Soc Clin Oncol*, 2014, 32 (dopl.), LBA3 (abstrakt).
- 10 Lenz, H. – Niedzwiecki, D. – Innocenti, F., et al.: CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyse untreated metastatic adenocarcinoma of the colon or rectum. ESMO 2014, abstrakt 5010.
- 11 Heskamp, S. – Boerman, O. C. – Molkenboer-Kuening, J. D., et al.: Bevacizumab reduces tumor targeting of anti-epidermal growth factor and anti-insulinlike growth factor 1 receptor antibodies. *Int J Cancer*, 2013, 133, s. 307–314.
- 12 Norguet, E. – Dahan, L. – Gaudart, J., et al.: Cetuximab after bevacizumab in metastatic colorectal cancer: is it the best sequence? *Dig Liver Dis*, 2011, 43, s. 917–919.

## Léčebné možnosti metastatického kolorektálního karcinomu

MUDr. Jiří Bartoš, MBA | MUDr. Igor Richter, Ph.D.

Komplexní onkologické centrum Krajské nemocnice Liberec, a. s.

- 1 Douillard, J. Y. – Cunningham, D. – Roth, A. D., et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. *Lancet*, 2000, 355, s. 1041–1047.
- 2 de Gramont, A. – Figuer, A. – Seymour, M., et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. *J Clin Oncol*, 2000, 18, s. 2938–2947.
- 3 Van Cutsem, E. – Hoff, P. M. – Harper, P., et al.: Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised phase III trials. *Br J Cancer*, 2004, 90, s. 1190–1197.
- 4 Cassidy, J. – Clarke, S. – Diaz-Rubio, E., et al.: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. *J Clin Oncol*, 2008, 26, s. 2006–2012.
- 5 Tournigand, C. – André, T. – Achille, E., et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. *J Clin Oncol*, 2004, 22, s. 229–237.
- 6 Grothey, A. – Sargent, D. – Goldberg, R. M. – Schmolli, H. J.: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil, leucovorin, irinotecan, and oxaliplatin in the course of treatment. *J Clin Oncol*, 2004, 22, s. 1209–1214.
- 7 Falkone, A. – Ricci, S. – Brunetti, I., et al.: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. *J Clin Oncol*, 2007, 25, s. 1670–1676.
- 8 Souglakos, J. – Androulakis, N. – Syrigos, K., et al.: FOLFOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). *Br J Cancer*, 2006, 94, s. 798–805.
- 9 Cremolini, C. – Loupakis, F. – Masi, G., et al.: FOLFOLFOXIRI/bevacizumab versus FOLFIRI/bevacizumab as first-line treatment in unresectable metastatic colorectal cancer: results of phase III TRIBE trial by GONO Group. *Ann Oncol*, 2013, 24, dopl. 4, s. iv21.
- 10 Seymour, M. T. – Maughan, T. S. – Ledermann, J. A., et al.: Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. *Lancet*, 2007, 370, s. 143–152.
- 11 Junker, D. J. – O'Callaghan, C. J. – Karapetis, C. S., et al.: Cetuximab for the treatment of colorectal cancer. *N Engl J Med*, 2007, 357, s. 2040–2048.
- 12 Karapetis, C. S. – Khambata-Ford, S. – Junker, D. J., et al.: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med*, 2008, 359, s. 1757–1765.
- 13 Van Cutsem, E. – Peeters, M. – Siena, S., et al.: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. *J Clin Oncol*, 2007, 25, s. 1658–1664.
- 14 Cunningham, D. – Humblet, Y. – Siena, S., et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. *N Engl J Med*, 2004, 351, s. 337–345.

- 15 Van Cutsem, E. – Köhne, C. H. – Hitre, E., et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med*, 2009, 360, s. 1408–1417.
- 16 Van Cutsem, E. – Köhne, C. H. – Lámg, I., et al.: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. *J Clin Oncol*, 2011, 29, s. 2011–2019.
- 17 Ciardiello, F. – Lenz, H. J. – Köhne, C. H., et al.: Effect of KRAS and NRAS mutational status on first-line treatment with FOLFIRI plus cetuximab in patients with metastatic colorectal cancer (mCRC): new results from the CRYSTAL trial. *J Clin Oncol*, 2014, 32, dopl. 3, abstrakt LBA443.
- 18 Bokemeyer, C. – Bondarenko, I. – Makhson, A., et al.: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. *J Clin Oncol*, 2009, 27, s. 663–671.
- 19 Maughan, T. S. – Adams, R. A. – Smith, C. G., et al.: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. *Lancet*, 2011, 377, s. 2103–2114.
- 20 Tveit, K. M. – Guren, T. – Glimelius, B., et al.: Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. *J Clin Oncol*, 2012, 30, s. 1755–1762.
- 21 Ciardiello, S. – Lenz, H. J. – Köhne, C. H., et al.: Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: new results from the OPUS study. *J Clin Oncol*, 2014, 32 (dopl. 3).
- 22 Venook, A. – Niedzwiecki, H. – Lenz, H. J., et al.: CALGB/SWOG 8040. *Annals of Oncol*, 2014, 25, s. ii105–ii117.
- 23 Douillard, J. Y. – Siena, S. – Cassidy, J., et al.: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. *J Clin Oncol*, 2010, 28, s. 4697–4705.
- 24 Douillard, J. Y. – Oliner, K. S. – Siena, S., et al.: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. *N Engl J Med*, 2013, 369, s. 1023–1034; *Oncol*, 2014, 32, dopl. 3, abstrakt LBA444.
- 25 Tol, J. – Koopman, M. – Cats, A., et al.: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. *N Engl J Med*, 2009, 360, s. 563–572.
- 26 Grothey, A. – Van Cutsem, E. – Sombrero, A., et al.: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet*, 2013, 381, s. 303–312.
- 27 Li, J. – Qin, S. – Yau, T., et al.: CONCUR: a randomized double-blind placebo controlled phase 3 study of regorafenib monotherapy in Asian patients with previously treated metastatic colorectal cancer (mCRC). *Ann Oncol*, 2014, 25 (dopl. 2), s. ii114–ii115.
- 29 Tebbutt, N. C. – Wilson, K. – Gebbs, V. J., et al.: Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomised Phase III MAX Study. *J Clin Oncol*, 2010, 28, s. 3191–3198.
- 29 Hurwitz, H. – Fehrenbacher, L. – Novotny, W., et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med*, 2004, 350, s. 2335–2342.
- 30 Kabbinnavar, F. – Irl, C. – Zurlo, A. – Hurwitz, H.: Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. *Oncology*, 2008, 75, s. 215–223.
- 31 Cunningham, D. – Lang, I. – Marcuello, E., et al.: Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. *Lancet Oncol*, 2013, 14, s. 1077–1085.
- 32 Saltz, L. B. – Clarke, S. – Diaz-Rubio, E., et al.: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. *J Clin Oncol*, 2008, 26, s. 2013–2019.
- 33 Giantonio, B. – Catalano, P. J. – Metropoul, N. J., et al.: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. *J Clin Oncol*, 2007, 25, s. 1539–1544.
- 34 Van Cutsem, E. – Tabernero, J. – Lakomy, R., et al.: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. *J Clin Oncol*, 2012, 30, s. 3499–3506.
- 35 Bennouna, J. – Sastre, J. – Arnold, D., et al.: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. *Lancet Oncol*, 2013, 14, s. 29–37.
- 36 Heinemann, V. – Fischer von Weikersthal, L. – Decker, T., et al.: Randomised comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). *J Clin Oncol*, 2013, 31, dopl. 3, abstrakt LBA3506.
- 37 Stintzig, S. – Jung, A. – Rossius, L., et al.: Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. *Eur J Cancer*, 2013, 49, dopl. 3, LBA 17.
- 38 Heinemann, V. – Modest, D. – Fischer von Weikersthal, L., et al.: Independent radiologicalevaluation of objective response early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306). *Ann Oncol*, 2014, 25, dopl. 2, s. ii117.
- 39 Nordlinger, B. – Skrbte, H. – Glimelius, B., et al.: Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. *Lancet Oncol*, 2013, 14, s. 1208–1215.
- 40 Koopman, M. – Simkens, L. – May, A. M., et al.: Final results and subgroup analyses of the phase 3 CAIRO3 study: maintenance treatment with capecitabine + bevacizumab versus observation after induction treatment with chemotherapy + bevacizumab in metastatic colorectal cancer (mCRC). *J Clin Oncol*, 2014, 32, dopl. 3, abstrakt 3504, s. 5s.
- 41 Arnold, D. – Graeven, U. – Lerchenmuller, C. A., et al.: Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): a phase III noninferiority trial (AIO KRK 0207). *J Clin Oncol*, 2014, 32, dopl. 3, abstrakt 3503, s. 5s.

## Systemová terapie nádorů hlavy a krku

MUDr. Zdeněk Mechl, CSc. | MUDr. Dagmar Brančíková Interní hematologická a onkologická klinika LF MU a FN Brno-Bohunice

- 1 Vermorken, J. B.: What is the role of induction chemotherapy in locally advanced head and neck cancer in 2013. ICHNO Barcelona 2013, abstrakt SP-012.
- 2 Baxi, S. S. – O'Neill, V. C. – Herman, E. J., et al.: Trends in chemoradiation use in elderly patients with head and neck cancer. Changing treatment patterns with cetuximab. *Head Neck*, 22. 12. 2014 (Epub před tiskem).
- 3 Burtneß, B. A.: This house believes that radiotherapy should be combined with cetuximab but not with chemotherapy in patients with locally advanced HPV+ oropharyngeal cancer. For the motion. *Radiotherapy and Oncology*, 2015, 114 (dopl. 1), SP 046.
- 4 *National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology*, verze 2.2014.
- 5 Rosenthal, D. J. – Bonner, J. A., et al.: Impact p16 status on the results of the phase III cetuximab/radiotherapy. ASCO 2014, abstrakt 6002.
- 6 Cmelak, A.: Reduced IMRT in human papilloma virus—associated resectable oropharyngeal squamous carcinomas after clinical complete response to induction chemotherapy. ASCO 2014, abstrakt 6006.
- 7 Haddad, R., et al.: Induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone in locally advanced head and neck cancer: a randomized phase 3 trial. *Lancet Oncol*, 2013, 14, s. 257–263.
- 8 Posner, M. R.: Integrating systemic agents into multimodality treatment of locally advanced head and neck cancer. *Ann Oncol*, 2010, 21 (dopl. 7), s. 240–251.
- 9 Hitt, R., et al.: A randomised phase III trial comparing induction chemotherapy followed by either chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. *Ann Oncol*, 2014, 25, s. 216–225.
- 10 Lefebvre, O. – Pointreau, Y. – Rolland, F., et al.: Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation. The TREMPIN, randomised Phase II study. *J Clin Oncol*, 2013, 31, s. 853–856.
- 11 Ghi, M. G. – Paccagnella, A. – Ferrari, D., et al.: Cancer treatment (CRT or cetuximab) with or without induction TPF in locally advanced head and neck cancer. ICHNO 2015, abstrakt OC 006.
- 12 Mehra, R.: Association of XPF and HPV among squamous cell head and neck tumors biomarkers analysis of ECOG 3303. The European Cancer Congress 2013, abstrakt 3152.
- 13 Seiwert, T. Y. – Fayette, J. – Cupissol, D., et al.: A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. *Ann Oncol*, 2014, 25, 9, s. 1813–1820.
- 14 Machiels, J. P., et al.: LUX head and neck 1: afatinib vs methotrexate in recurrent/metastatic SCCHN. ESMO 2014, abstrakt LBA29.
- 15 Vermorken, J. B. – Psyrri, A. – Mesia, A., et al.: Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. *Ann Oncol*, 2014, 25, s. 801–807.
- 16 Burtneß, B. – Goldwasser, M. S. A. – Flood, W., et al.: ECOG phase II randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic, recurrent head and neck cancer. *J Clin Oncol*, 2005, 23, s. 8646–8654.
- 17 Vermorken, J. B.: osobní sdělení, 2015.
- 18 Veronesi, U. – Cascinelli, N. – Adamo, J. – Mechl, Z., et al.: A randomised study of adjuvant chemo- and immunotherapy in cutaneous malignant melanoma. *New Engl J Med*, 1982, 306, s. 913–916.
- 19 Seiwert, T., et al.: KEYNOTE-012: Pembrolizumab for patients with recurrent/metastatic SCCHN. ASCO 2014, abstrakt 6011.
- 20 Seifert, T., et al.: PD-1 drugs doubles responses in head and neck cancer. ASCO 2015, abstrakt LBA 8008.
- 21 Velho, P. H. I. – Astro, G. – Chung, Ch. H.: Targeting the P13 pathway in head and neck squamous cell carcinoma. ASCO 2015, studijní texty.
- 22 Peyrade, F., et al.: Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: Review of the literature and proposal for management changes. *Oral Oncol*, 2013, s. 482–491.

# Výživa onkologických pacientů

MUDr. Petra Holečková, Ph.D., MBA

Ústav radiační onkologie Nemocnice Na Bulovce a 1. LF UK, Praha

- 1 Tisková zpráva ČTK, 2. 6. 2015.
- 2 Klener, P. – Vorlíček, J.: *Podpůrná léčba v onkologii*. Galén, 1998, s. 31–50.
- 3 Muscaritolim, M. – Anker, S. D. – Argilés, J.: Consensus definitiv of sarcopenia, cachexia and precachexia: Joint dokument elaborated by Special Interest Groups (SIG) „cachexia – anorexia in chronic casting diseases“ and „nutrition in geriatrics“. *Clinical Nutrition*, 2010, 29, s. 154–159.
- 4 Holečková, P. – Novotný, J.: Výživa onkologicky nemocných. In: Novotný, J. – Vítek, P., et al.: *Onkologie v klinické praxi*. Mladá Fronta, 2012, s. 512–522
- 5 Dostupné z: [www.linkos.cz/pracovni-skupina-nutricni-pecce-v-onko-logii-pri-cos/materialy-pro-praxi-ke-stazeni/](http://www.linkos.cz/pracovni-skupina-nutricni-pecce-v-onko-logii-pri-cos/materialy-pro-praxi-ke-stazeni/), vyhledáno 29. 7. 2015.
- 6 Mercadante, S.: Parenteral versus enteral nutrition in cancer patient: indications and practice. *Support care cancer*, 1998, 2, s. 85–93.
- 7 Heyland, D. K. – MacDonald, S. – Keefe, L.: Total parenteral nutrition in the critically ill patient. *JAMA*, 1998, 280, s. 2013.
- 8 Heys, S. D. – Park, K. G. – Garlick, P. J.: Nutrition and malignant disease: implication for surgical practice. *Br J Surg*, 1992, 79, s. 614–623.
- 9 Norman, K. – Pichard, C. – Lochs, H. – Pirlich, M.: Prognostic impact of disease-related malnutrition. *Clin Nutr*, 2008, 27, s. 5–15. Epub 3. 12. 2007.
- 10 Heys, S. D. – Walker, L. G. – Smith, I.: Enteral nutritional supplementation with key nutrients in patients with critical illness and cancer a meta-analysis of randomized controlled clinical trials. *Annals of Surgery*, 1999, 229, s. 467–477.
- 11 Starke, J. – Schneider, H. – Altheid, B.: Short-term individual nutritional care as part of routine clinical setting improves outcome and quality of life in malnourished medical patients. *Clinical Nutrition*, 2011, 30, s. 194–201.
- 12 Holečková, P. – Beneš, P. – Deus, M. – Štěpánek, L.: Význam individualizované nutriční péče v onkologické ambulanci, grant AVKV, XXXI. Mezinárodní kongres SKVIMP a 1. česko-slovenský kongres klinické výživy, 7. 3. 2015, Hradec Králové.
- 13 Přehled nutričních ambulančí, [www.skvimp.cz](http://www.skvimp.cz).

## Průlomová bolest z pohledu radiačního onkologa

MUDr. Magda Macháňová Komplexní onkologické centrum, Krajská nemocnice Liberec, a. s.

- 1 Dennis, K. – Makhani, L. – Zeng, L., et al.: Single fraction conventional external beam radiation therapy for bone metastases: A systematic review of randomized controlled trials. *Radiother Oncol*, 2013, 106, s. 5–14.
- 2 Hakl, M.: Novinky v terapii bolesti. *Klinická farmakologie a farmacie*, 2012, 26, s. 102–105.
- 3 Haugen, D. F. – Hjermstad, M. J. – Hagen, N., et al.: European Palliative Care Research Collaborative (EPCRC). Assessment and classification of cancer breakthrough pain: a systematic literature review. *Pain*, 2010, 149, s. 476–482, Doi: 10.1016/j.pain.2010.02.035.
- 4 Kabelka, L. – Kozák, J. – Lejčko, J., et al.: Doporučený postup pro léčbu průlomové nádorové bolesti. *Bolest*, 2011, 14, dopl. 1, s. 1–5.
- 5 Kleeberg, U. R. – Mercadante, S. – Davies, A., et al.: Pan-European, open-label dose titration study of fentanyl buccal tablet in patients with breakthrough cancer pain. *Eur Journal of Pain*, 2015, 19, s. 528–537.
- 6 Li, K. K. – Hadi, S. – Kirou-Mauro, A., et al.: When should we define the response rates in the treatment of bone metastases by palliative radiotherapy? *Clin Oncol (R Coll Radiol)*, 2008, 15, s. 211–218.
- 7 Nosková, P.: Průlomová bolest a její léčba. *Interní medicína pro praxi*, 2010, 12, s. 482–486.
- 8 Popovic, M. – den Hartogh, M. – Zhang, L., et al.: Review of international patterns of practice for the treatment of painful bone metastases with palliative radiotherapy from 1993 to 2013. *Radiother Oncol*, 2014, 111, s. 11–17.
- 9 Radbruch, L. – Trottenberg, P. – Elsner, F., et al.: A systematic review of the role of alternative application routes for opioid treatment for moderate to severe cancer pain: an EPCRC opioid guidelines project. *Palliat Med*, 2011, 25, s. 578–596.
- 10 Ryu, S. – Fang, Y. – Rock, J., et al.: Pain control by image-guided radio-surgery for solitary spinal metastasis. *J Pain Symptom Manage*, 2008, 35, s. 292–298.
- 11 Spencer, K. – Morris, E. – Dugdale, A., et al.: 30 day mortality in adult palliative radiotherapy—A retrospective population based study of 14,972 treatment episodes. *Radiother Oncol*, 2015, 115, s. 264–271.
- 12 Sochor, M. – Sláma, O.: Management chronické a akutní bolesti u pacientů s nádorovými chorobami. *Klinická onkologie*, 2015, 28, s. 94–98.
- 13 Vondráčková, D.: Průlomová bolest – klinický obraz a léčení. *Neurologie pro praxi*, 2009, 10, s. 310–313.

## Dolforin v léčbě silné chronické bolesti u onkologických pacientů

prof. MUDr. Jindřich Fínek, Ph.D. Onkologická a radioterapeutická klinika FN a LF UK, Plzeň

- 1 Doležal, T. – Hakl, M. – Kozák, J., et al.: Metodické pokyny pro farmakoterapii bolesti. *Bolest*, 2009, 2, s. 3–36.
- 2 Kozák, J.: Nové názory na dlouhodobou léčbu opioidy. *Neurol Prax*, 2008, 9, s. 42–46.
- 3 Zecca, E. – Manzoni, A. – Centurioni, F., et al.: Pharmacokinetic study between a bilayer matrix fentanyl patch and monolayer matrix fentanyl patch: single dose administration in healthy volunteers. *Format Br J Clin Pharmacol*, 22. 1. 2015, doi: 10.1111/bcp.12595.
- 4 Lejčko, J.: Silné opioidy v léčbě chronické bolesti. *Neurol Prax*, 2006, 3, s. 141–144.
- 5 SPC Dolforin. SÚKL, květen 2014, [www.sukl.cz](http://www.sukl.cz).

## Léčba bendamustinem: znovuzrození starého léku

MUDr. Kateřina Steinerová | doc. MUDr. Daniel Lysák, Ph.D. | MUDr. Pavel Jindra, Ph.D.

Hematologicko-onkologické oddělení, FN Plzeň

- 1 National Center for Biotechnology Information. PubChem Compound Database; CID=77082, <https://pubchem.ncbi.nlm.nih.gov/compound/77082>, vyhledáno 17. 9. 2015.
- 2 Leoni, L. M. – Hartley, J. A.: Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity. *Semin Hematol*, 2011, 48, dopl. 1, s. S12–S23.
- 3 Cephalon (2008) receives FDA approval for Treanda to treat patients with relapsed indolent non-Hodgkin's lymphoma [media release]. 2008 Oct 31 [online]. Dostupné z: [www.cephalon.com/media/news-releases/](http://www.cephalon.com/media/news-releases/), vyhledáno 17. 9. 2015.
- 4 [www.sukl.cz](http://www.sukl.cz), vyhledáno 17. 9. 2015.
- 5 Tajeja, N.: Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma. *Clin Med Insights Oncol*, 2011, 5, s. 145–156.
- 6 McCloskey, J. K. – Broome, C. M. – Cheson, B. D.: Safe and effective treatment of aggressive non-hodgkin lymphoma with rituximab and bendamustine in patients with severe liver impairment. *Clin Adv Hematol Oncol*, 2013, 11, s. 184–188.
- 7 Dewilde, S. – Woods, B. – Castaigne, J. G., et al.: Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales. *J Med Econ*, 2014, n 17, s. 111–124.
- 8 Howlader, N. – Noone, A. M. – Krapcho, et al.: *SEER Cancer Statistics Review 1975–2009* (Vintage 2009 Populations). Bethesda, National Cancer Institute, 2011, <http://seer.cancer.gov>.
- 9 Hallek, M. – Cheson, B. D. – Catovsky, D., et al.: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCCN) 1996 guidelines. *Blood*, 2008, 111, s. 5446–5456.
- 10 Salvi, F. – Miller, M. D. – Grilli, A., et al.: A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. *J Am Geriatr Soc*, 2008, 56, s. 1926–1931.
- 11 Keating, M. J. – O'Brien, S. – Albitar, M., et al.: Early results of a chemioimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. *J Clin Oncol*, 2005, 23, s. 407–488.
- 12 Hallek, M. – Fischer, K. – Fingerle-Rowson, G., et al.: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. *Lancet*, 2010, 376, s. 1164–1174.

- 13 **Knauf, W. U. – Lissichkov, T. – Aldaoud, A., et al.:** Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. *J Clin Oncol*, 2009, 27, s. 4378–4384.
- 14 **Eichhorst, B. – Fink, A. M. – Busch, R., et al.:** Frontline chemioimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): Final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study). *Blood*, 2014, 124, abstrakt.
- 15 **Kahl, B.:** Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma. *Semin Hematol*, 2008, 45, s. 90–94.
- 16 **Brad, S. – Kahl, N. L. – Bartlett, J. P., et al.:** Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-hodgkin lymphoma. *Cancer*, 1. 1. 2010.
- 17 **Lidia, G. L. – Kazmierczak, M. – Kroll-Balcerzak, R., et al.:** Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma. *Med Oncol*, 2014, 31, s. 944.
- 18 **Herold, M. – Schulze, A. – Niederwieser, D., et al.:** Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). *J Cancer Res Clin Oncol*, 2006, 132, s. 105–112.
- 19 **Rummel, M. J. – Niederle, N. – Maschmeyer, G., et al.:** Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open label, multicentre, randomised, phase 3 non-inferiority trial. *Lancet*, 2013, 381, s. 1203–1210.
- 20 **Kumar, S. K. – Rajkumar, S. V. – Dispenzieri, A., et al.:** Improved survival in multiple myeloma and the impact of novel therapies. *Blood*, 2008, 111, s. 2516–2520.
- 21 **Pönisch, W. – Mitrou, P. S. – Merkle, K., et al.:** Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone—a randomized phase III study of the East German Study Group of Haematology and Oncology (OSHO). *J Cancer Res Clin Oncol*, 2006, 132, s. 205–212.
- 22 **Pönisch, W. – Bourgeois, M. – Moll, B., et al.:** Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. *J Cancer Res Clin Oncol*, 2013, 139, s. 499–508.
- 23 **Kumar, S. – Krishnan, A. – LaPlant, B., et al.:** Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma. *Am J Hematol*, 2. 9. 2015, doi: 10.1002/ajh.24181.